Vascular extracellular signal-regulated kinase mediates migraine-related sensitization of meningeal nociceptors

Annals of Neurology

Volumn 73, Issue 6, 2013, Pages 741-750

  Zhang, Xichun ^a,b   Kainz, Vanessa ^a   Zhao, Jun ^a,b   Strassman, Andrew M ^a,b   Levy, Dan ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; MITOGEN ACTIVATED PROTEIN KINASE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL ARTERY; MENINGEAL NOCICEPTOR; MIGRAINE; NONHUMAN; PAIN RECEPTOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TRIGEMINUS GANGLION;

ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MENINGES; MIGRAINE DISORDERS; NITRIC OXIDE DONORS; NOCICEPTORS; RATS; RATS, SPRAGUE-DAWLEY; TRIGEMINAL GANGLION;

EID: 84881223075     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23873     Document Type: Article

References (58)

1. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27: 193-210.
2. Blau JN, Dexter SL,. The site of pain origin during migraine attacks. Cephalalgia 1981; 1: 143-147.
3. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P,. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009; 8: 679-690.
4. Strassman AM, Levy D,. Response properties of dural nociceptors in relation to headache. J Neurophysiol 2006; 95: 1298-1306.
5. Messlinger K,. Migraine: where and how does the pain originate? Exp Brain Res 2009; 196: 179-193.
6. Strassman AM, Raymond SA, Burstein R,. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996; 384: 560-564.
7. Levy D, Strassman AM,. Distinct sensitizing effects of the cAMP-PKA second messenger cascade on rat dural mechanonociceptors. J Physiol 2002; 538: 483-493.
8. Levy D, Jakubowski M, Burstein R,. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A 2004; 101: 4274-4279.
9. Olesen J, Thomsen LL, Iversen H,. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 1994; 15: 149-153.
10. Sances G, Tassorelli C, Pucci E, et al. Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia 2004; 24: 110-119.
11. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD,. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 2008; 131 (pt 8): 2192-2200.
12. Iversen HK, Olesen J,. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia 1996; 16: 412-418.
13. Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003; 106: 461-470.
14. Martelletti P, Stirparo G, Morrone S, et al. Inhibition of intercellular adhesion molecule-1 (ICAM-1), soluble ICAM-1 and interleukin-4 by nitric oxide expression in migraine patients. J Mol Med 1997; 75: 448-453.
15. Bergerot A, Holland PR, Akerman S, et al. Animal models of migraine: looking at the component parts of a complex disorder. Eur J Neurosci 2006; 24: 1517-1534.
16. Magis D, Bendtsen L, Goadsby PJ, et al. Evaluation and proposal for optimization of neurophysiological tests in migraine: Part 2. Neuroimaging and the nitroglycerin test. Cephalalgia 2007; 27: 1339-1359.
17. Dodick DW,. Examining the essence of migraine-is it the blood vessel or the brain? A debate. Headache 2008; 48: 661-667.
18. Levy D, Burstein R, Strassman AM,. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005; 58: 698-705.
19. Levy D, Burstein R,. The vascular theory of migraine: leave it or love it? Ann Neurol 2011; 69: 600-601.
20. Charles A,. Migraine is not primarily a vascular disorder. Cephalalgia 2012; 32: 431-432.
21. Zhang XC, Kainz V, Burstein R, Levy D,. Tumor necrosis factor-α induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions. Pain 2011; 152: 140-149.
22. Zimmermann M,. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-110.
23. Zhang X, Strassman AM, Burstein R, Levy D,. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther 2007; 322: 806-812.
24. Levy D, Zhang XC, Jakubowski M, Burstein R,. Sensitization of meningeal nociceptors: inhibition by naproxen. Eur J Neurosci 2008; 27: 917-922.
25. Levy D, Burstein R, Strassman AM,. Mast cell involvement in the pathophysiology of migraine headache: a hypothesis. Headache 2006; 46 (suppl 1): S13-S18.
26. Levy D, Burstein R, Kainz V, et al. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007; 130: 166-176.
27. Iversen HK, Olesen J, Tfelt-Hansen P,. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38: 17-24.
28. Read SJ, Manning P, McNeil CJ, et al. Effects of sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion in the rat. Implications for antimigraine mechanisms. Brain Res 1999; 847: 1-8.
29. Reuter U, Bolay H, Jansen-Olesen I, et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001; 124 (pt 12): 2490-2502.
30. Komalavilas P, Shah PK, Jo H, Lincoln TM,. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 1999; 274: 34301-34309.
31. Doronzo G, Viretto M, Russo I, et al. Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: influence of insulin resistance and oxidative stress. Atherosclerosis 2011; 216: 44-53.
32. Maddahi A, Ansar S, Chen Q, Edvinsson L,. Blockade of the MEK/ERK pathway with a raf inhibitor prevents activation of pro-inflammatory mediators in cerebral arteries and reduction in cerebral blood flow after subarachnoid hemorrhage in a rat model. J Cereb Blood Flow Metab 2011; 31: 144-154.
33. Maddahi A, Edvinsson L,. Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway. BMC Neurosci 2008; 9: 85.
34. Maddahi A, Edvinsson L,. Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway. J Neuroinflammation 2010; 7: 14.
35. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
36. Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol 2011; 69: 635-645.
37. Hansen JM, Pedersen D, Larsen VA, et al. Magnetic resonance angiography shows dilatation of the middle cerebral artery after infusion of glyceryl trinitrate in healthy volunteers. Cephalalgia 2007; 27: 118-127.
38. Gozalov A, Jansen-Olesen I, Klaerke D, Olesen J,. Role of BK(Ca) channels in cephalic vasodilation induced by CGRP, NO and transcranial electrical stimulation in the rat. Cephalalgia 2007; 27: 1120-1127.
39. Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 2008; 28: 226-236.
40. Loppnow H, Buerke M, Werdan K, Rose-John S,. Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J Cell Mol Med 2011; 15: 484-500.
41. Reuter U, Chiarugi A, Bolay H, Moskowitz MA,. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002; 51: 507-516.
42. Jones MG, Lever I, Bingham S, et al. Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat. Cephalalgia 2001; 21: 643-655.
43. Koulchitsky S, Fischer MJ, De Col R, et al. Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat-possible implications for the pathophysiology of headaches. J Neurophysiol 2004; 92: 1320-1328.
44. Koulchitsky S, Fischer MJ, Messlinger K,. Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia 2009; 29: 408-417.
45. De Col R, Koulchitsky SV, Messlinger KB,. Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus. Neuroreport 2003; 14: 229-232.
46. Martin RS, Martin GR,. Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC). Cephalalgia 2001; 21: 46-52.
47. Offenhauser N, Zinck T, Hoffmann J, et al. CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 2005; 25: 225-236.
48. Lin Q, Palecek J, Paleckova V, et al. Nitric oxide mediates the central sensitization of primate spinothalamic tract neurons. J Neurophysiol 1999; 81: 1075-1085.
49. Roch M, Messlinger K, Kulchitsky V, et al. Ongoing activity in trigeminal wide-dynamic range neurons is driven from the periphery. Neuroscience 2007; 150: 681-691.
50. Greenfield JC Jr, Rembert JC, Tindall GT,. Transient changes in cerebral vascular resistance during the Valsalva maneuver in man. Stroke 1984; 15: 76-79.
51. Williams B,. Cerebrospinal fluid pressure changes in response to coughing. Brain 1976; 99: 331-346.
52. De Felice M, Ossipov MH, Wang R, et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 2010; 133 (pt 8): 2475-2488.
53. De Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 2010; 67: 325-337.
54. De Felice M, Porreca F,. Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia 2009; 29: 1277-1284.
55. Raddant AC, Russo AF,. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med 2011; 13: e36.
56. MacGregor EA,. Oestrogen and attacks of migraine with and without aura. Lancet Neurol 2004; 3: 354-361.
57. Boes T, Levy D,. Influence of sex, estrous cycle and estrogen on intracranial dural mast cells. Cephalalgia 2012; 32: 924-931.
58. Baun M, Pedersen MH, Olesen J, Jansen-Olesen I,. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia 2012; 32: 337-345.